0RNK Stock Overview
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Inventiva S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €3.03 |
| 52 Week High | €4.75 |
| 52 Week Low | €2.14 |
| Beta | 0.96 |
| 1 Month Change | -10.57% |
| 3 Month Change | -14.60% |
| 1 Year Change | 39.71% |
| 3 Year Change | -73.17% |
| 5 Year Change | 7.51% |
| Change since IPO | -57.60% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0RNK | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -4.1% | -0.4% | 2.2% |
| 1Y | 39.7% | -29.1% | 0.9% |
Return vs Industry: 0RNK exceeded the UK Biotechs industry which returned -29.1% over the past year.
Return vs Market: 0RNK exceeded the UK Market which returned 0.9% over the past year.
Price Volatility
| 0RNK volatility | |
|---|---|
| 0RNK Average Weekly Movement | 9.2% |
| Biotechs Industry Average Movement | 6.8% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: 0RNK's share price has been volatile over the past 3 months.
Volatility Over Time: 0RNK's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 122 | Frederic Cren | www.inventivapharma.com |
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.
Inventiva S.A. Fundamentals Summary
| 0RNK fundamental statistics | |
|---|---|
| Market cap | €158.11m |
| Earnings (TTM) | -€110.43m |
| Revenue (TTM) | €23.16m |
6.8x
P/S Ratio-1.4x
P/E RatioIs 0RNK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0RNK income statement (TTM) | |
|---|---|
| Revenue | €23.16m |
| Cost of Revenue | €1.02m |
| Gross Profit | €22.15m |
| Other Expenses | €132.57m |
| Earnings | -€110.43m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Sep 25, 2024
| Earnings per share (EPS) | -2.12 |
| Gross Margin | 95.61% |
| Net Profit Margin | -476.73% |
| Debt/Equity Ratio | -148.3% |
How did 0RNK perform over the long term?
See historical performance and comparison